Brief: Cyclo Therapeutics Announces Design Of Pivotal Phase 3 Study Evaluating Trappsol Cycl In Niemann-Pick Type C1
27/04/2021 14:34
April 27 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS ANNOUNCES DESIGN OF PIVOTAL PHASE 3
STUDY
EVALUATING TRAPPSOL® CYCLO™ IN NIEMANN-PICK TYPE C1
Source text for Eikon: ID:nBw8sD5ta
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug